OrthoPediatrics reported record Q2 2026 revenue of $70.5 million, a 15% increase year-over-year, driven by strong growth in Trauma & Deformity products and international sales. The company improved adjusted EBITDA to $6.8 million and significantly reduced free cash flow usage by 78%. It also raised its full-year 2026 revenue guidance to $265-269 million, expecting 12-14% growth and breakeven free cash flow. This reflects confidence in its pediatric orthopedic market leadership and ongoing innovation.
Sabre has already implemented agentic AI in travel booking and servicing through its MCP server, launched in 2025, enabling real-time AI-driven travel sales and support. With nearly 80 customers including Virgin Australia and Flight Centre, Sabre's t...
A global IBM study reveals 60% of employees worry AI is diminishing their skills, especially critical thinking. While CHROs emphasize the need for judgment in AI oversight, employees rank it lower, highlighting a skills perception gap. Nearly half of...
Bitcoin's price has risen to $80,402, marking a steady upward trend supported by buyers who have consistently raised the market floor since June. This growth has increased the percentage of Bitcoin supply in profit from 45% to 71%, signaling more hol...
Bitcoin recently closed above its 50-week moving average for the first time in 45 weeks, a key technical indicator suggesting the bear market may be over. The cryptocurrency rose nearly 6% in the week, trading around $81,450, and has gained 29% over ...
Pendle has introduced the NGI+ market, allowing DeFi users to trade fixed and variable yields on tokenized private infrastructure assets managed by Partners Group, which oversees $186 billion in assets. The NGI+ token offers a fixed yield of about 19...
